Obesity Series Live

CME Infromation: Pharmacotherapy of Obesity

Pharmacotherapy of Obesity: Practical Applications for Clinical Care

 

    

Presented by Boston University School of Medicine in collaboration with PlatformQ Health Education, LLC and The Obesity Society

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Novo Nordisk.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and PlatformQ Health Education, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Activity

Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PROGRAM OVERVIEW
Obesity has been acknowledged as a global health crisis. In the United States, recent national estimates suggest that 36% of adults and 17% of youths meet national criteria to be classified as obese. Obesity impacts many other medical conditions including diabetes, cardiovascular disease, and orthopedic issues. The need for health care professionals to slow the epidemic of obesity has long been a significant clinical challenge. Many health care providers ascribe the inability to lose weight to a lack of patient adherence to weight management therapies, particularly lifestyle change. Yet, there are many complex factors impacting the inability to reverse obesity beyond simple adherence issues that are difficult to recognize, much less address clinically. The critical first step is accepting that obesity is a disease, not a behavior. Clinicians must then be prepared to learn and utilize different approaches to this long-standing clinical challenge. Currently, only one-third of obese patients ever receive an obesity diagnosis and fewer than one-quarter receive counseling on diet, weight reduction, or exercise. A survey of US primary care providers revealed that physicians treating these patients have little confidence in their ability to manage obesity. In 2013, the American Medical Association published a policy stating that obesity was a disease and thus required a range of medical interventions to advance treatment and prevention. Major medical societies have recently issued guidelines for obesity management with an expanded emphasis on a number of treatments, particularly pharmacologic and surgical, to address the suboptimal clinical management of obese patients. Pharmacotherapy for obesity is an important tool when properly used by trained providers based on scientific evidence, established indications and guidelines for titration and therapeutic outcomes assessment. The goal of this program is to identify obesity as a disease and prepare health care providers to use available pharmacological treatment options to treat obesity when lifestyle interventions are deemed to be insufficient. With the recent advances in pharmacologic treatments for obesity, clinicians require current information regarding their modes of action, efficacy and safety profiles and guidance in choosing among available medications.

TARGET AUDIENCE
The intended audience for this activity consists of health care providers of people who may be obese and need pharmacotherapeutic interventions and includes the following groups:

  • Providers: Physicians (primary care and those of relevant specialties such as endocrinology or cardiology), nurse practitioners, physician assistants
  • Lifestyle specialists: Mental health providers, dietitians/nutritionists, exercise professionals

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Identify obesity as a disease, not a behavioral problem, and consider the implications of that paradigm shift on attitudes toward treating the condition
Identify indications that lifestyle interventions have not been sufficient to result in weight loss
Describe the pharmacology of, and indications for, the use of the currently available medications for chronic weight management
Describe ongoing management of people using anti-obesity medications, including means to gauge both therapeutic efficacy or the need to consider bariatric surgery

 

DATE OF RELEASE/EXPIRATION
Live Internet Activity

Wednesday, June 7, 2017, from 12:00 PM EST – 1:00 PM EST

Enduring Material
The enduring material will be available from June 7, 2017 – December 7, 2017

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

FACULTY
Caroline M. Apovian, MD, FACP, DABOM (Course Director)

Director, Center for Nutrition and Weight Management, Boston Medical Center
Professor of Medicine and Pediatrics, Section of Endocrinology, Diabetes, and Nutrition
Boston University School of Medicine
Boston, Massachusetts

Scott Kahan, MD, MPH
Director, National Center for Weight Loss and Wellness
Washington, DC

Kimberly A. Gudzune, MD, MPH
Assistant Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland

CME Course Advisor:
Amanda Velazquez, MD
Nutrition and Obesity Medicine Fellow
Endocrinology, Diabetes and Nutrition
Boston Medical Center
Boston, Massachusetts

DISCLOSURE POLICY
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

FINANCIAL DISCLOSURES

Presenters Disclosures
Caroline M. Apovian, MD, FACP, DABOM (Course Director)

Consultant: Merck; Nutrisystem; Zafgen; sanofi-aventis; Orexigen; EnteroMedics; Scientific Intake; Gelesis; Ferring; Takeda; Novo Nordisk

Research funding: Aspire Bariatrics; GI Dynamics; Pfizer; Gelesis; Orexigen; MetaProteomics; Takeda; MYOS Corporation; The Dr. Robert C. and Veronica Atkins Foundation

Stockholder: Science Smart, LLC

Scott Kahan, MD, MPH

Consultant: Novo Nordisk; Takeda; Orexigen; Eisiai

Kimberly A. Gudzune, MD, MPHKimberly A. Gudzune, MD, MPH

Has no relevant financial relationships to disclose.

Boston University School of Medicine Peer Reviewer Disclosures
Amanda Velazquez, MD Has no relevant financial relationships to disclose.
Boston University School of Medicine Program Managers Disclosures
Elizabeth Drury Has no relevant financial relationships to disclose.
Boston University School of Medicine Program Managers Disclosures
Elizabeth Drury Has no relevant financial relationships to disclose.
PlatformQ Health Education, LLC Disclosures
Agnes Yang, MD, Medical Director Has no relevant financial relationships to disclose.
Karen Greb-Murphy, Program Manager Has no relevant financial relationships to disclose.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLAIMERS (if applicable):

ALL PROGRAMS, ACTIVITIES, AND MATERIALS PROVIDED BY BOSTON UNIVERSITY OFFICE OF CONTINUING MEDICAL EDUCATION OR ITS ASSOCIATES ARE PROVIDED ON THE CONDITION THAT THEY BE USED SOLELY FOR EDUCATIONAL PURPOSES BY QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE CONTINUING MEDICAL EDUCATION PROGRAMS, ACTIVITIES OR MATERIALS. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Boston University School of Medicine, ObesitySeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION:
Please send CME inquiries to: cme@bu.edu

For issues with your CME Certificate, Please contact ObesitySeriesLive at 977–394–1306 or at Support@ObesitySeriesLive.com

CME Information: Obesity Management Perspectives

Expert Obesity Management Perspectives and Updates from ObesityWeekSM

Jointly provided by Boston University School of Medicine and PlatformQ Health Education, LLC

   

 

ACKNOWLEDGEMENT
This activity is not supported by any commercial interest or grantors.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and PlatformQ Health Education, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, November 11, 2016 from 12:00PM – 1:00PM ET
Enduring Material
The enduring material will be available from November 11, 2016 – May 11, 2017

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply the approach that obesity is a disease, not a behavioral problem, and in that context more identify more effective collaborative methods to overcome patient barriers to following an optimized weight management plan
Identify the indications for each of the spectrum of obesity treatments, including lifestyle interventions, pharmacotherapy, and surgery for individualized obesity management
Describe the pharmacology of the currently available medications for obesity, their indications and adverse effect profile, and how to initiate and titrate them as part of an effective obesity treatment program
Describe key clinical reports from ObesityWeekSM 2016

 

TARGET AUDIENCE
This activity is intended for primary care physicians, gastroenterologists, surgeons, pharmacists, nurses, nurse practitioners and other clinicians involved in the treatment and management of obesity.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.obesityserieslive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Caroline Apovian, MD, FACP, FACN

Research:Aspire Bariatrics, MetaProteomics, Takeda, Pfizer, Gelesis, Atkins Foundation, GI Dynamics, Lilly, and Orexigen, MYOS Corporation
Consultant:Merck, Nutrisystem, Orexigen, Sanofi-Aventis, EnteroMedics, Scientific Intake, Gelesis, Ferring, Takeda, Novo Nordisk and Zafgen

W. Scott Butsch, MD MSc

None

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Amanda Velazquez, MD, CME Course Director None
Elizabeth Drury, Program Manager None
Randi O’Hara, Program Manager None
Agnes Lee None

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMERS
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION
Accreditation Support:
Please contact the Boston University School of Medicine at www.bucme.org.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact ObesitySeriesLive at 877-394-1306 or at Support@ObesitySeriesLive.com

Disclaimer:
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

CME Information: Lung Cancer EGFR

Updates in Lung Cancer:
Targeting Epidermal Growth Factor Receptor

 

 

ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, September 7, 2016 from 10:00AM EST – 11:00AM EST
Enduring Material

The enduring material will be available from Wednesday, September 7, 2016 to Tuesday, March 7, 2016.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Review the pathophysiology of NSCLC and the role played by EGFR and activating EGFR mutations
Provide the rationale for EGFR mutation testing to identify appropriate patients for targeted therapy
Evaluate currently approved EGFR inhibitors and their role in the treatment of NSCLC
Discuss the adverse events common to this drug class and how individual drugs might differ, and present management strategies

 

INTENDED AUDIENCE
Oncologists, oncology nurses, nurse practitioners, physician assistants, internists, primary care physicians, pulmonologists, and other health care professionals who treat patients with lung cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
Geoffrey R. Oxnard, MD

Has nothing to disclose.

 

Providers Disclosures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
 

Peer Reviewer Disclsoures
Rasim A. Gucalp, MD To be posted prior to the live internet activity
PlatformQ Health Education, LLC Disclsoures
Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity
Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

 

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support:
For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

 

CME Information: Lung Cancer ALK

Updates in Lung Cancer:
ALK Inhibition in the Treatment of NSCLC

 

ACKNOWLEDGEMENT
This educational activity is supported by an educational grant from Ariad Pharmaceuticals, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, September 7, 2016 from 11:00AM EST – 12:00PM EST
Enduring Material
The enduring material will be available from Wednesday, September 7, 2016 to Tuesday, March 7, 2016

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Provide rationale for testing for ALK mutations and use of ALK inhibitors
Evaluate latest clinical data on new and emerging ALK inhibitors and combinations for use in patients with NSCLC
Manage resistance to ALK inhibitors with appropriate second-line options

 

TARGET AUDIENCE
Medical oncologists, radiation oncologists, GI surgeons, GI internists, fellows and other health care professionals (primary care physicians, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with gastric cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
Geoffrey R. Oxnard, MD

Has nothing to disclose.

 
Providers Disclosures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
 
Peer Reviewer Disclsoures
Rasim A. Gucalp, MD To be posted prior to the live internet activity
PlatformQ Health Education, LLC Disclsoures
Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity
Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

 

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support:
For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

 

CME Information: Gastric Cancer

Individualizing Care For Patients with Advanced/Metastatic Gastric Cancer

 

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

TUITION

Complimentary

ACCREDITATION STATEMENT

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS


Live Internet Activity


Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material


Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program

DATE OF RELEASE/EXPIRATION


Live Activity


Wednesday, August 31, 2016 from 2:00 PM EST – 3:00 PM EST

Enduring Material


The enduring material will be available from August 31, 2016 to February 28, 2017.

LEARNING OBJECTIVES


At the conclusion of this activity, participants will be able to:

Identify and select effective chemotherapy agents for treatment-naive patients with metastatic gastric cancer
Evaluate the safety and efficacy of available and emerging targeted therapies in the first-line setting for advanced/metastatic gastric cancer
Examine new and promising data from available and emerging treatment options in the second-line setting


TARGET AUDIENCE


Medical oncologists, radiation oncologists, GI surgeons, GI internists, fellows and other health care professionals (primary care physicians, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with gastric cancer.


ESTIMATED TIME TO COMPLETE



This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION


There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
David I. Ilson, MD

Consulting Fee: Novartis; Roche; Genentech; Lilly

Manish A. Shah, MD

Consulting Fee: Lilly

Contracted Research: Sanofi; Genentech; Berg; Boston Biomedical

 

 

Peer Reviewer Disclsoures
Amit K. Verma, MD Has no disclosures to report relevant to this activity.
 

 

Providers Disclosures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
 

 

PlatformQ Health Education, LLC Disclsoures
Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity
Karen Greb-Murphy, Program Manager Has nothing to disclose relevant to this activity.


DISCLAIMERS (if applicable):


The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION

Accreditation Support:


Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support:


For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

CME Information: Pediatric Neuroblastoma

 

Pediatric Patients with High-Risk Neuroblastoma:
Perspectives on Diagnosis and Management

 

  

ACKNOWLEDGEMENT
This activity is supported by United Therapeutics.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, June 9, 2016 from 12:00PM ET – 1:00PM ET.
Tuesday, September 20, 2016 from 12:00PM ET – 1:00PM ET.

Enduring Material
The enduring material will be available from June 9, 2016 to September 20, 2017.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Review treatment options for the management of high-risk pediatric neuroblastoma, including chemotherapy, surgery, radiotherapy, and immunological treatments
Manage immediate and late effects of therapy for pediatric neuroblastoma
Describe patient-related needs associated with agents used for high-risk pediatric neuroblastoma
Evaluate current evidence-based practice and research topics regarding the care of pediatric patients with high-risk neuroblastoma
Provide collaborative comprehensive care for patients with high-risk pediatric neuroblastoma
Counsel patients and caregivers to look for potential treatment outcomes in order to effectively address immediate and late effects of treatment

TARGET AUDIENCE
This activity is intended for oncologists, surgeons, nurses, pharmacists, physician assistants, and health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship:
Navin Pinto, MD

None

Jennifer Saggio, MSN, CRNP, CPON

Speaker’s Bureau: United Therapeutics

Jason Shohet, MD, PhD

None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship:
Hamsa Jaganathan Medical Director PlatformQ Health Education, LLC Has nothing to disclose.

 

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMERS (if applicable):
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION
Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

CME Information: HER2 Positive Breast Cancer

Updates on HER2 Positive
Breast Cancer Management

 


ACKNOWLEDGEMENT

This educational activity is supported by an educational grant from Genentech.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, June 10, 2016 from 1:00PM EST- 2:00PM EST
Enduring Material

The enduring material will be available from June 10, 2016 to June 10, 2017.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize the efficacy and safety of new and emerging treatment approaches for HER2 positive breast cancer in the neoadjuvant, adjuvant and metastatic settings
Evaluate therapeutic challenges associated with HER2-targeted treatment, including resistance, toxicity and optimal duration of treatment

 

TARGET AUDIENCE
Oncologists, hematologist-oncologists, radiation oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other healthcare professionals who treat patients with breast cancer

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
Harold Burstein, MD, PhD

To be posted prior to the live internet activity

Eric Winer, MD

To be posted prior to the live internet activity

Providers Disclosures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
Peer Reviewer Disclosures
Jesus Anampa Mesias, MD To be posted prior to the live internet activity
PlatformQ Health Education, LLC Disclosures
Hamsa Jaganathan, Medical Director To be posted prior to the live internet activity
Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

 

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

CME Information: Breast Cancer ASCO

Advances in Breast Cancer Management:
Updates from ASCO 2016

 

  

ACKNOWLEDGEMENT
This activity is supported by Puma Biotechnology.

TUITION Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, June 10, 2016 from 12:00PM ET – 1:00PM ET.
Enduring Material

The enduring material will be available from June 10, 2016 – December 10, 2016.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Describe the efficacy and safety of new and emerging treatment approaches for HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings
Summarize the efficacy and safety of new and emerging targeted treatment approaches for patients with advanced breast cancer who have developed endocrine resistance
Evaluate how biomarkers are being used to select treatment regimens that may be particularly effective in patients with TNBC
Select appropriate combinations of chemotherapy and endocrine therapy in the neoadjuvant and adjuvant setting for patients with breast cancer

TARGET AUDIENCE
This activity is intended for medical oncologists, surgical oncologists, pathologists, general surgeons, medical fellows, pharmacists, oncology nurse practitioners/physician assistants, and other clinicians involved in the diagnosis and treatment of breast cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship:
Harold J. Burstein, MD, PhD

None

 
Name of Planner Reported Financial Relationship:
Anne Roc PhD, Medical Director Has nothing to disclose.

 

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The following PlatformQ Health Education, LLC planner, Shaina Druy, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMERS (if applicable):
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION
Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

CME Information: Pancreatic Cancer

Advances and Ambitions in the Management of
Metastatic Pancreatic Cancer

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Incyte Corporation and Merrimack Pharmaceuticals.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, December 11, 2015 from 10:00 AM EST – 12:00 PM EST

Enduring Material

The enduring material will be available from December 11, 2015 to June 11, 2016.

ACTIVITY DESCRIPTION
Pancreatic cancer is the 4th leading cause of death from cancers in the US, and remains one of the most lethal cancers. Prognosis is poor for 80-85% of patients owing to heterogeneity and aggressive nature of the disease, old age, late diagnosis and late initiation of treatment, sub- optimal drug delivery, treatment toxicity, development of drug resistance, and limited efficacy of systemic treatments. Therapeutic approaches should be individualized due to patient and treatment related issues, but optimizing treatment for individual patients with metastatic pancreatic cancer is an ongoing challenging. Furthermore, treatment strategies are evolving and understanding the practical application of recent advances from clinical studies can be overwhelming. This program aims to improve clinician confidence in their ability to provide timely and accurate care to patients with metastatic pancreatic cancer through discussions on treatment guidelines, combination therapy options, anticipating and recognizing treatment-related toxicities, mechanisms of treatment resistance, and treatment modification to improve patient outcomes.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Determine sequence and timing of initial and subsequent strategies with single agents and in the adjuvant setting to maximize treatment response in patients with MPC
Address chemotherapy induced toxicities and provide supportive care options for patients undergoing treatment for MPC
Describe the mechanisms of chemotherapy resistance in pancreatic tumors
Summarize emerging treatment options, biomarkers, and imaging techniques in clinical development for recurrent and refractory pancreatic cancer

INTENDED AUDIENCE
This activity is intended for medical oncologists, oncology nurses, and other health care professionals involved in the diagnosis and treatment of pancreatic cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
Eileen O’Reilly, MD

Research grants: Abbott Laboratories, Amgen, Bayer, CASI, Celgene, Eli Lilly and Company/Imclone, Exelixis, Genentech, Immunomedics, Incyte, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, and Vicus Therapeutics
Consulting: Aduro Biotech, Array, Astellas Pharma US, BioAlliance, Boston Scientific, Boston Therapeutics, BMS, CASI, Celgene, Cipla, Eli Lilly and Company, EMD Sorono, Gilead, IntegraGen, Medergy, MedImmune, Merrimack, Momenta, Novartis, Onxeo, Pharmacyclics, Sanofi-aventis, Silenseed, Sillajen, and Vicus Therapeutics.

Tanios Bekaii-Saab, MD

Consulting: Merrimack, Merck KGaA

University of Nebraska Medical Center, Center for Continuing Education
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health, Inc
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

 

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA- approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

Techincal Support:
For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

CME Information: Multiple Myeloma

Emerging Therapies for Multiple Myeloma

 

 

ACKNOWLEDGEMENT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol-Myers Squibb, and Karyopharm Therapeutics, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, April 13, 2016, from 11:00 AM EST – 12:00 PM EST
Enduring Material
The enduring material will be available from April 13, 2016 – October 13, 2016.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

ACTIVITY DESCRIPTION
Multiple myeloma accounts for 1.5% of all cancers and approximately 13% of all hematologic malignancies. In the United States, annual new cases of multiple myeloma are estimated at 24,050, with 11,090 deaths annually. While advances in the treatment of multiple myeloma have led to improvements in response rates and increased survival, disease relapse is inevitable for the majority of patients and multiple myeloma recurs more aggressively with each relapse, eventually leading to treatment-refractory disease. Recent significant advances in the understanding of underlying biology of MM have expanded diagnostic, prognostic, and treatment options. In 2015, multiple treatment strategies were approved for use in relapsed/refractory multiple myeloma. These emerging strategies contribute to an increasingly complex treatment paradigm. New agents, with diverse mechanisms of action are creating opportunities to target multiple pathways, overcome resistance, and improve clinical outcomes. Incorporating these novel agents into treatment regimens will lead to more effective and less toxic therapies. However, busy physicians are challenged to remain current on the latest MM data on new and emerging agents. Improved understanding of disease prognostic factors as well as the efficacy and safety data of new and emerging agents will allow clinicians to integrate these agents effectively into appropriate treatment regimens. Expert guidance, in tandem with continuing medical education, will be critical in helping physicians navigate the current therapeutic landscape for multiple myeloma, thus improving outcomes for patients with MM.

Assess the comparative safety and efficacy of emerging/investigational agents for the treatment of relapsed/refractory multiple myeloma
Discuss the therapeutic implications of combination regimens involving emerging agents with currently available treatment options
Identify barriers to the optimal management of patients with relapsed/refractory multiple myeloma and how such barriers may be successfully addressed
Describe treatment plans for patients newly relapsed or refractory to current treatment options

INTENDED AUDIENCE
This activity is intended for US-based hematologists, oncologists, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients multiple myeloma.


ESTIMATED TIME TO COMPLETE

This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

Presenters: Disclosures:
Shaji Kumar, MD

Funding for clinical trials provided to institution: Celgene, Takeda, Novartis, Amgen, AbbVie, Sanofi, Janssen

Advisory board participation with payments to institution: Celgene, Takeda, Amgen, AbbVie, Janssen, GlycoMimetics

Advisory board participation with personal reimbursement: Noxxon Pharma, Kesios Therapeutics, Skyline

David Dingli, MD, PhD

Research support: Karyopharm Therapeutics, Inc.

  

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health, Inc
Anne Roc PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

 

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
lease contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com